Evaluating DPP4 inhibition and Bioequivalence of Vildagliptin 100mg SR ft Prof. Dr Aravinda Jagadeesha Dr. Nandita Mohan2 Jan 2023 10:45 AM IST Vildagliptin, a potent dipeptidyl peptidase IV inhibitor (DPP-4i), is usually administered twice daily to provide >90% inhibition of DPP-4 over...
Hetero Labs, Optimus proposal to launch generic Paxlovid rejected by CDSCO panel: Report Dr. Divya Colin27 Jan 2022 6:10 PM ISTNew Delhi: In a major setback to Hetero Labs and Optimus Pharma, Subject Expert Committee (SEC) functional under the Central Drugs Standard Control...
Conduct clinical trial in Indian patient: CDSCO panel tells Glenmark on pulmonary drug study Medical Dialogues Team17 Dec 2021 6:43 PM ISTNew Delhi: The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has directed Glenmark to conduct a Phase 3...
Include cardiology parameters in clinical trial of anti diabetic drug Lobeglitazone: CDSCO panel tells Glenmark Medical Dialogues Team22 Jun 2021 2:54 PM ISTNew Delhi: In accordance with the proposal presented by pharma major, Glenmark, on the anti-diabetic drug molecule, Lobeglitazone Sulphate Tablets,...
CDSCO panel asks Hetero to resubmit Bioequivalence protocol for Trelagliptin Succinate tablet MD Bureau30 Dec 2020 7:12 PM ISTNew Delhi: Noting that the protocol was not scientifically designed and the safety of the study subjects was not taken care of, the Subject Expert...
